EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Circulating microRNAs in association with pancreatic cancer risk within 5 years

Cong Wang, Hui Cai, Qiuyin Cai, Jie Wu, Rachael Stolzenberg-Solomon, Xingyi Guo, Claire Zhu, Yu-Tang Gao, Jordan Berlin, Fei Ye iD, Wei Zheng, Veronica Wendy Setiawan und 1 weitere

International Journal of Cancer · 2024

DOI: 10.1002/ijc.34956 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, 2024. Verfasst von Cong Wang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Epidemiology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Circulating MicroRNA, Biomarkers, Tumor. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, Foundation for the National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Early detection is critical for improving pancreatic cancer prognosis. Our study aims to identify circulating microRNAs (miRNAs) associated with pancreatic cancer risk. The two‐stage study used plasma samples collected ≤5 years prior to cancer diagnosis, from case–control studies nested in five prospective cohort studies. The discovery stage included 185 case–control pairs from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Replication stage samples comprised 277 pairs from Shanghai Women's Health Study/Shanghai Men's Health Study, Southern Community Cohort Study, and Multiethnic Cohort Study. Seven hundred and ninety‐eight miRNAs were measured using the NanoString nCounter Analysis System. Odds ratios (OR) and 95% confidence intervals (CI) for per 10% change in miRNAs in association with pancreatic cancer risk were derived from conditional logistic regression analysis in discovery and replication studies, separately, and then meta‐analyzed. Stratified analysis was conducted by age at diagnosis (2 years). In the discovery stage, 120 risk associated miRNAs were identified at p < .05. Three were validated in the replication stage: hsa‐miR‐199a‐3p/hsa‐miR‐199b‐3p, hsa‐miR‐767‐5p, and hsa‐miR‐191‐5p, with respective ORs (95% CI) being 0.89 (0.84–0.95), 1.08 (1.02–1.13), and 0.90 (0.85–0.95). Five additional miRNAs, hsa‐miR‐640, hsa‐miR‐874‐5p, hsa‐miR‐1299, hsa‐miR‐22‐3p, and hsa‐miR‐449b‐5p, were validated among patients diagnosed at ≥65 years, with OR (95% CI) of 1.23 (1.09–1.39), 1.33 (1.16–1.52), 1.25 (1.09–1.43), 1.28 (1.12–1.46), 0.76 (0.65–0.89), and 1.22 (1.07–1.39), respectively. The miRNA targets were enriched in pancreatic carcinogenesis/progression‐related pathways. Our study suggests that circulating miRNAs may identify individuals at high risk for pancreatic cancer ≤5 years prior to diagnosis, indicating its potential utility in cancer screening and surveillance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsCirculating MicroRNABiomarkers, TumorHumansFemaleMaleMiddle AgedCase-Control StudiesAgedProspective StudiesRisk FactorsEarly Detection of CancerMicroRNAsPrognosis

Stichwörter der Autor:innen

biomarkercirculating microRNAearly detectionpancreatic cancerplasma

Substanzen

Circulating MicroRNABiomarkers, TumorMicroRNAs

Autor:innen und Institutionen

  • Division of Epidemiology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Metabolic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, USA.
  • Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland, USA.
  • Department of Epidemiology, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
  • Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

ORCID-Profile: Fei Ye, Xiao-Ou Shu

Förderung

  • NCI NIH HHS
  • Foundation for the National Institutes of Health

Zitieren

APA

Wang, C., Cai, H., Cai, Q., Wu, J., Stolzenberg-Solomon, R., Guo, X., Zhu, C., Gao, Y. T., Berlin, J., Ye, F., Zheng, W., Setiawan, V. W., & Shu, X. O. (2024). Circulating microRNAs in association with pancreatic cancer risk within 5 years. International Journal of Cancer. https://doi.org/10.1002/ijc.34956

Vancouver

Wang C, Cai H, Cai Q, Wu J, Stolzenberg-Solomon R, Guo X, et al. Circulating microRNAs in association with pancreatic cancer risk within 5 years. International Journal of Cancer. 2024. doi:10.1002/ijc.34956

BibTeX
@article{Wang2024,
  author = {Wang, Cong and Cai, Hui and Cai, Qiuyin and Wu, Jie and Stolzenberg-Solomon, Rachael and Guo, Xingyi and Zhu, Claire and Gao, Yu-Tang and Berlin, Jordan and Ye, Fei and Zheng, Wei and Setiawan, Veronica Wendy and Shu, Xiao-Ou},
  title = {Circulating microRNAs in association with pancreatic cancer risk within 5 years},
  journal = {International Journal of Cancer},
  year = {2024},
  doi = {10.1002/ijc.34956}
}
Kostenlos starten →